Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491538 | 0.96 | HTR2C (0.39) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL4485561 | 0.96 | HTR2C (0.39) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL34468227 | 0.82 | ALDH1A1 (0.40) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL12714452 | 0.80 | TMEM97 (0.44) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL12715076 | 0.80 | HTR2B (0.45) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL4486412 | 0.80 | TMEM97 (0.44) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL12715110 | 0.80 | HTR2B (0.45) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL12714484 | 0.80 | TMEM97 (0.44) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL10229055 | 0.80 | HTR2B (0.45) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL4479747 | 0.80 | HTR2A (0.42) | KMT2AMEN1NPC1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504390-B2 | Benzoxazepine derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2009-03-17 | — | — | US | disclosed |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | N.V. ORGANON (NL) | 2008-06-12 | — | — | US | disclosed |
| EP-1399450-B1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | ORGANON NV (NL) | 2008-03-19 | — | — | EP | disclosed |
| US-7307073-B2 | Benzoxazepines derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2007-12-11 | — | — | US | disclosed |
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | MERCK SHARP & DOHME B.V. (NL) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | CHRNA4, CHRNA10, CHRNA9 | KMT2A 2555/4885MEN1 4866/4885NPC1 2380/4885 |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | GRIN1, GRIA4, CHRNA4 | KMT2A 2258/4885MEN1 4584/4885NPC1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.